In Brief: Sequus Doxil
Executive Summary
Sequus Doxil: Increase in shelf life of liposomal doxorubicin from 14 to 20 months is approved by FDA July 10. Sequus submitted a supplemental NDA for the change May 7, 1996. Doxil was approved in late 1995 for second-line treatment of Kaposi's sarcoma in people with AIDS ("The Pink Sheet" Nov. 27, 1995, p. 7)...